文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞激活蛋白PET显像在胸膜间皮瘤中的预后价值

Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
PubMed 文献 · J Nucl Med · 2026-03-02

本研究基于FAPI PET观察性试验(NCT04571086),纳入39例恶性胸膜间皮瘤患者,比较68Ga-FAPI-46与18F-FDG PET/CT的预后价值。单因素分析显示两种显像的所有体积参数均与生存显著相关,多因素分析显示MTV是独立预后标志物。结论认为两种显像的MTV预后价值相似,高MTV为独立风险因素。

要点

  • 68Ga-FAPI-46与18F-FDG PET/CT的MTV均为独立预后标志物。
  • 单因素分析中两种显像的所有体积参数均与生存显著相关。
  • FAP IRS较高与较差生存相关,但多因素分析无显著差异。

核心结论

  • 在恶性胸膜间皮瘤探索性队列中,68Ga-FAPI-46与18F-FDG PET/CT测定的MTV具有相似预后价值,高MTV为独立风险因素。

研究设计与样本

  • 基于FAPI PET观察性试验(NCT04571086),2020年5月至2024年1月招募49例疑似或确诊恶性间皮瘤患者,39例纳入分析。
  • 所有患者均在4周内完成68Ga-FAPI-46与18F-FDG PET/CT,半自动测量肿瘤负荷并计算SUVmax、SUVmean及体积参数。
  • 对19例肿瘤样本计算FAP免疫反应评分(IRS),按修订版mRECIST 1.1评估总生存与无进展生存。

主要发现

  • 单因素分析显示68Ga-FAPI-46和18F-FDG的所有体积参数均有显著生存差异,例如68Ga-FAPI-46 MTV为262天 vs 737天(P=0.008),18F-FDG MTV为336天 vs 760天(P=0.012)。
  • 多因素分析显示MTV是68Ga-FAPI-46的独立预后标志物(风险比4.44;95%CI 1.20-16.43;P=0.025)。
  • 多因素分析显示MTV是18F-FDG的独立预后标志物(风险比7.01;95%CI 1.29-38.2;P=0.024)。
  • Kaplan-Meier分析显示FAP IRS较高与较差生存相关(IRS 0-3为438天 vs IRS 4-12为1076天;P=0.04),但单因素和多因素分析均无显著差异。

临床怎么用

  • 68Ga-FAPI-46 PET/CT不仅可补充诊断流程,还提供预后价值,并可能为患者提供替代性诊疗一体化策略。

局限性

  • 本研究为样本量有限的探索性队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High expression of fibroblast activation protein (FAP) has been associated with inferior survival in several tumor entities. Novel 68Ga-radiolabeled FAP inhibitors (68Ga-FAPIs) allow noninvasive measurement of FAP, which enables the development of prognostic imaging parameters from 68Ga-FAPI PET/CT. In this study, we compared the prognostic value of 68Ga-FAPI-46 with 18F-FDG PET in a cohort of patients with malignant pleural mesothelioma from the FAPI PET observational trial (NCT04571086). Methods: Between May 2020 and January 2024, 49 patients with suspected or proven malignant mesothelioma were recruited, 39 of whom were eligible for data analysis. All patients underwent 68Ga-FAPI-46 and 18F-FDG PET/CT less than 4 wk apart. Tumor burden was measured semiautomatically, and SUVmax, SUVmean, and volumetric parameters (metabolic tumor volume [MTV], total lesion glycolysis/total lesion fibroblast activation, and total tumor SUV) were calculated. The FAP immunoreactive score (IRS) was calculated for tumor samples from a subset of patients (n = 19). Overall survival and progression-free survival were assessed per revised mRECIST (version 1.1). Survival analyses were performed with univariate and multivariate Cox regression and with Kaplan-Meier curves for clinical and imaging parameters, stratified by median. Results: Univariate analysis showed significant survival differences for all volumetric parameters for 68Ga-FAPI-46 and 18F-FDG (e.g., 68Ga-FAPI-46 MTV, 262 d vs. 737 d; P = 0.008 vs. 18F-FDG MTV, 336 d vs. 760 d; P = 0.012). Multivariate analysis revealed that MTV was an independent prognostic marker for 68Ga-FAPI-46 (hazard ratio, 4.44; 95% CI, 1.20-16.43; P = 0.025) and 18F-FDG (hazard ratio, 7.01; 95% CI, 1.29-38.2; P = 0.024). Kaplan-Meier analysis of the FAP IRS found that a higher IRS was associated with poorer survival (438 d with an IRS of 0-3 vs. 1,076 d with an IRS of 4-12; P = 0.04), but no significant difference was observed in univariate and multivariate analyses. Conclusion: In this modest exploratory cohort of patients with malignant pleural mesothelioma, MTV determined by 68Ga-FAPI-46 and 18F-FDG PET/CT had similar prognostic value, and high MTV was an independent risk factor. 68Ga-FAPI-46 not only complements a diagnostic work-up but also provides prognostic value and could offer alternative theranostic strategies for these patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kessler L, Schwaning F, Metzenmacher M, et al. Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma. J Nucl Med. 2026. PMID: 41506801. doi:10.2967/jnumed.125.270906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。